Pharmacokinetics and pharmacogenetics of the MEK1/2 inhibitor, selumetinib, in Asian and Western healthy subjects: a pooled analysis

PURPOSE: Emerging data on selumetinib, a MEK1/2 inhibitor in clinical development, suggest a possible difference in pharmacokinetics (PK) between Japanese and Western patients. This pooled analysis sought to assess the effect of ethnicity on selumetinib exposure in healthy Western and Asian subjects...

Descripción completa

Detalles Bibliográficos
Autores principales: Dymond, Angela W., Elks, Cathy, Martin, Paul, Carlile, David J., Mariani, Gabriella, Lovick, Susan, Huang, Yifan, Lorch, Ulrike, Brown, Helen, So, Karen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Pharmacokinetics and Disposition
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5423974/
https://www.ncbi.nlm.nih.gov/pubmed/28283692
http://dx.doi.org/10.1007/s00228-017-2217-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5423974/
https://www.ncbi.nlm.nih.gov/pubmed/28283692
http://dx.doi.org/10.1007/s00228-017-2217-3

Ejemplares similares